BillionToOne, Inc.

BillionToOne, Inc. is a precision diagnostics company that quantifies biology to develop advanced molecular diagnostic tests. Its molecular counting platform is engineered to detect and measure DNA molecules at the single-molecule level, enabling more accurate and sensitive disease detection.

• In May, BillionToOne, Inc. introduced Unity Confirm™, a non-invasive assay that uses circulating fetal cells from a maternal blood sample to confirm high-risk prenatal screening results. The test leverages the company’s Fetal Cell Capture™ technology to isolate intact fetal cells with high precision.

• The assay enables clinicians to confirm high-risk findings through a simple maternal blood draw, reducing the need for invasive procedures such as chorionic villus sampling (CVS) or amniocentesis. By avoiding these traditional methods, Unity Confirm™ helps minimize potential risks to the pregnancy while supporting accurate prenatal diagnosis.

• BillionToOne, Inc. reported total revenue of $108.4 million in the first quarter of 2026, representing an 84% increase from $59.0 million in the same quarter of 2025. The strong year-over-year growth reflects expanding adoption of the company’s molecular diagnostic offerings and continued momentum across both prenatal and oncology testing services.

• Prenatal clinical testing revenue reached $96.5 million during the first quarter of 2026, rising 72% compared with the first quarter of 2025. The substantial increase highlights continued demand for the company’s prenatal diagnostic solutions, driven by broader physician adoption, growing test utilization, and ongoing expansion of its commercial testing portfolio.

• Oncology clinical testing revenue totaled $10.7 million in the first quarter of 2026, more than four times higher than the $2.2 million reported a year earlier. The sharp increase demonstrates accelerating growth in the company’s oncology business and reflects rising adoption of its advanced cancer diagnostic testing solutions in clinical settings.

• Gross profit margin improved to 73% in the first quarter of 2026, compared with 64% in the same period of 2025, marking a 9 percentage-point year-over-year increase. The improvement reflects enhanced operational efficiency, stronger scale advantages, and a more favorable testing mix contributing to higher overall profitability and financial performance.

• The company delivered 188,000 tests in the first quarter of 2026, representing a 44% increase from 131,000 tests delivered during the first quarter of 2025. The higher testing volume underscores expanding customer demand, broader market penetration, and continued growth across the company’s prenatal and oncology diagnostic testing businesses.

Acrobull Recommendation Based on Evaluation